- Home
- APPS vs FHTX Comparison
APPS vs FHTX Comparison
Compare APPS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- FHTX
- Stock Information
- Founded
- APPS 2007
- FHTX 2015
- Country
- APPS United States
- FHTX United States
- Employees
- APPS N/A
- FHTX N/A
- Industry
- APPS Multi-Sector Companies
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- APPS Miscellaneous
- FHTX Health Care
- Exchange
- APPS Nasdaq
- FHTX Nasdaq
- Market Cap
- APPS 428.8M
- FHTX 513.7M
- IPO Year
- APPS N/A
- FHTX 2020
- Fundamental
- Price
- APPS $1.31
- FHTX $8.01
- Analyst Decision
- APPS Hold
- FHTX Strong Buy
- Analyst Count
- APPS 4
- FHTX 5
- Target Price
- APPS $2.38
- FHTX $16.00
- AVG Volume (30 Days)
- APPS 5.1M
- FHTX 134.3K
- Earning Date
- APPS 11-06-2024
- FHTX 11-04-2024
- Dividend Yield
- APPS N/A
- FHTX N/A
- EPS Growth
- APPS N/A
- FHTX N/A
- EPS
- APPS N/A
- FHTX N/A
- Revenue
- APPS $491,574,000.00
- FHTX $25,515,000.00
- Revenue This Year
- APPS N/A
- FHTX N/A
- Revenue Next Year
- APPS $9.83
- FHTX $8.77
- P/E Ratio
- APPS N/A
- FHTX N/A
- Revenue Growth
- APPS N/A
- FHTX N/A
- 52 Week Low
- APPS $1.29
- FHTX $2.70
- 52 Week High
- APPS $7.33
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- APPS 26.01
- FHTX 44.69
- Support Level
- APPS $1.31
- FHTX $8.52
- Resistance Level
- APPS $1.59
- FHTX $9.33
- Average True Range (ATR)
- APPS 0.23
- FHTX 0.70
- MACD
- APPS -0.20
- FHTX 0.00
- Stochastic Oscillator
- APPS 0.83
- FHTX 28.69
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.